论文部分内容阅读
目的探讨弥漫大B细胞性淋巴瘤(DLBCL)分子标记物Bcl-2、BAX及Survivin与美罗华疗效之间的关系。方法回顾性分析69例采用美罗华联合化疗治疗DLBCL患者的临床资料,探讨DLBCL分子标记物与美罗华疗效的关系。免疫组化SP法检测Bcl-2,BAX及Survivin蛋白的表达,分析其表达与美罗华疗效之间的关系。结果采用美罗华联合化疗治疗DLBCL患者的CR38例(55.1%),PR20例(28.9%),总有效率(CR+PR)为84.0%。Bcl-2表达阳性者的疗效明显好于阴性者(P=0.043);BAX及Survivin蛋白的表达则与美罗华疗效无关(P>0.05)。结论在美罗华联合化疗治疗的DLBCL患者中,Bcl-2表达阴性者的疗效较差,BAX及Survivin蛋白的表达则与疗效无关。
Objective To investigate the relationship between the molecular markers of diffuse large B cell lymphoma (DLBCL) Bcl-2, BAX and Survivin and the efficacy of rituximab. Methods The clinical data of 69 patients treated with rituximab combined with chemotherapy for DLBCL were retrospectively analyzed to investigate the relationship between DLBCL molecular markers and the curative effect of rituximab. The expression of Bcl-2, BAX and Survivin protein was detected by immunohistochemical SP method. The relationship between the expression of Bcl-2, BAX and Survivin protein and the curative effect of rituximab was analyzed. Results Among the 38 patients (55.1%) treated with rituximab combined with chemotherapy, 20 (28.9%) had PR (CR + PR), and the total effective rate (CR + PR) was 84.0%. The positive expression of Bcl-2 was significantly better than that of negative (P = 0.043). The expression of BAX and Survivin was not related to the efficacy of rituximab (P> 0.05). Conclusions Among patients with DLBCL treated with rituximab, the patients with negative Bcl-2 expression have poor efficacy and the expressions of BAX and Survivin protein have no correlation with the efficacy.